Novartis, a Swiss multinational pharmaceutical company, agreed to acquire Cellerys, a Zurich-based startup conducting research on a therapy to fight multiple sclerosis. Financial terms were not disclosed. "Under the agreement, Novartis will support the development of the CLS12311 therapy currently in Phase 2. Novartis will have the option to acquire Cellerys upon completion of a Phase 2 trial in the coming years," Cellerys.